Assembly Biosciences vs Enanta Pharmaceuticals
ASMB and ENTA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ASMB and ENTA compare
Assembly Biosciences is the larger company, worth 1.3 times as much as Enanta Pharmaceuticals ($430M against $320M).
Assembly Biosciences keeps more of each dollar of sales as profit, with a net margin of −16.6% compared with −96.9% at Enanta Pharmaceuticals.
Assembly Biosciences scores higher on the StockData Score (12 against 2 for Enanta Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ASMB | ENTA |
|---|---|---|
| Size and price | ||
| Market cap | $430M | $320M |
| Share price | $21.12 | $10.99 |
| Change, 1 year | −41.1% | −7.9% |
| Change, 5 years | −23.5% | −85.4% |
| Beta (5Y) | 1.17 | 1.14 |
| Employees | 73 | 120 |
| StockData Score | ||
| Total score | 12 (better) | 2 |
| Valuation score | 2 (better) | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 3 (better) | 1 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 6.4× | 4.9× (better) |
| P/B | 1.4× (better) | 3.2× |
| FCF yield | −9.5% (better) | −11.5% |
| Fair value | $22.88 | $9.32 |
| Margin of safety | 7.7% (better) | −17.9% |
| Growth | ||
| Revenue growth (TTM) | 80.2% | – |
| Revenue growth, 5Y average | −1.8% (better) | −11.8% |
| Profitability | ||
| Operating margin | −31.8% (better) | −90.0% |
| Net margin | −16.6% (better) | −96.9% |
| FCF margin | −60.7% | −56.6% (better) |
| Return on equity | −4.6% (better) | −70.1% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −4.5× |
| Current ratio | 12.89 (better) | 3.76 |
| Altman Z-score | 7.10 (better) | −0.97 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Buyback yield | 0.00% | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 92.1% | 93.6% |
| Held by insiders | 29.3% | 7.9% |
| Insider net buying, 12 months | −$252K | −$183K (better) |
| Short interest, % of float | 21.1% | 6.9% |
Go deeper
- ASMB stock overview
- ASMB income statement
- ASMB valuation and score
- ENTA stock overview
- ENTA income statement
- ENTA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.